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osting by EAbstract Background: Upgrade from VVI(R) to physiologic pacing offers beneﬁt to patients with
pacemaker syndrome (PMS). However, in asymptomatic patients with long term ventricular pacing
little is known regarding potential early hazards related to the acute changes in hemodynamics fol-
lowing upgrade.
Methods: Data of 28 patients who underwent upgrade of VVI(R) pacing were retrospectively ana-
lyzed. Mean time of ventricular pacing to upgrade was 6.3 ± 2.7 years. Indications of upgrade
included PMS (considered as necessary indication) in 9 patients, and unnecessary indications in
19 patients. Pacing was upgraded to DDD in 26 patients, VDD in 1 patient, and multisite pacing
in 1 patient. Three-month follow up data were reviewed. Intolerance to upgrade was deﬁned as
worsening of (or new onset) symptoms, hospital admissions or deaths following uncomplicated
upgrade procedures.
Results: Eleven patients (39.3%) were intolerant to upgrade. Intolerance to upgrade included pal-
pitations/dyspnea in 3 patients, hospitalization and death in 8 patients (1 patient with pulmonary
congestion related to underlying mitral stenosis and 6 patients with newly diagnosed myocardial
ischemia were hospitalized; two of whom died from acute ischemia, and 1 patient had out of
hospital sudden death). Patients with intolerance to upgrade were older than other patientsostafa Helmy St., Heliop olis,
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50 H. El-Damanhoury, O. Diab(p< 0.001), with more frequent unnecessary upgrades (p= 0.049), more rise in HR (p< 0.001),
and more preexisting undiagnosed myocardial ischemia (p= 0.001). Univariate logistic regression
analysis showed that age (p= 0.009) and HR increase (p= 0.004) were signiﬁcant predictors for
intolerance to upgrade.
Conclusions: Unnecessary pacing upgrade may not be tolerated. Pacing upgrade is recommended
to be individualized for selected patients.
ª 2012 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Superiority of dual chamber over ventricular pacing was ad-
dressed in several studies with conﬂicting results.1–4 However,
the physiologic beneﬁts of AV sequential activation have
caused dual chamber pacing to become common practice in
most patients with normal atrial activity.
Upgrade from ventricular to physiologic pacing is fre-
quently done in clinical practice in young patients with active
lifestyle and patients with pacemaker syndrome (PMS). It is
also practiced in asymptomatic patients with VVI(R) pacing
during battery exchange or lead replacement, which was previ-
ously described as ‘‘opportunistic upgrade’’.5,6 The restored
AV synchrony following the upgrade may result in acute rise
in heart rate and ventricular ﬁlling. While this can beneﬁt pa-
tients with PMS, little is known if asymptomatic patients
adapted to chronic VVI(R) pacing will tolerate the acute
hemodynamic changes following upgrade.
2. Methods
Twenty-eight patients who underwent pacing upgrade after
long term VVI(R) pacing (2–12 years) were included. Upgrade
was done during the period from January 2008 to December
2010. Preprocedural, procedural, and follow up data were ret-
rospectively reviewed and analyzed.
Preprocedural data were recorded including clinical assess-
ments, 12-lead surface electrocardiograms (ECGs), transthoracic
echocardiograms, and pacemaker (PM) check measurements
including battery status, ventricular lead impedance, pacing
threshold, and intrinsic electrogram. Pacing system upgrading
fromVVI/VVIR toDDD/VDDwas done in 27 patients for symp-
toms suspected to be relevant to PMS or during battery exchange
or lead replacement (opportunistic upgrade). Upgrading to multi-
site pacing was done during battery exchange in 1 patient with
worsened left ventricular ejection fraction (LVEF) reported on
echocardiogram.
2.1. Upgrade procedure
Periprocedural antibiotics were given to all patients. Backup
temporary pacing was done in PM dependant patients during
the procedure. Atrial leads were introduced via the ipsilateral
subclavian vein with active ﬁxation into the right atrial
appendage. In 1 patient, left ventricular (LV) lead was im-
planted in the posterolateral branch of coronary sinus. All bat-
teries were upgraded as planned and implanted in the
preexisting PM pockets. Battery status, lead impedances, pac-
ing thresholds, and intrinsic electrograms were measured. A P-
wave amplitude larger than 1.5 mV and a pacing threshold be-
low 1.5 V were considered acceptable. Patients were dischargedafter 1–2 days. Any procedure related complications were
recorded.
2.2. Follow up
Three month-follow up data were retrieved from patient re-
cords during follow up visits and hospital admissions including
clinical assessments, 12-lead surface ECGs, PM checks, and
any additional work up.
2.3. Deﬁnitions
Intolerance to upgrade was deﬁned by the occurrence of one of
the following: (1) new onset symptoms (or worsening of preex-
isting symptoms) including palpitations, chest pain, dyspnea,
or dizziness. (2) hospital admissions or deaths related to hemo-
dynamic consequences following uncomplicated upgrade pro-
cedures. Necessary indications for upgrade were deﬁned by
the presence of symptoms related to AV asynchrony (PMS),
while unnecessary indications were deﬁned as upgrade in
asymptomatic patients during battery exchange or lead
replacement (opportunistic upgrade) or in asymptomatic pa-
tients with worsened LVEF in whom upgrade to multisite pac-
ing was done.
Causes of clinical deterioration, hospitalization, or death
following PM upgrade were reported and analyzed.
2.4. Statistical analysis
Data were analyzed using SPSS software version 13. Categori-
cal variables were expressed as frequencies and percentages,
while continuous variables were expressed as means ± stan-
dard deviations. Comparison between categorical data was
done using Fisher’s exact test or Chi-square, while comparison
between continuous data was done using Student’s t test. Uni-
variate logistic regression analysis was used to deﬁne predictors
associated with clinical outcome. p-value was considered signif-
icant if 60.05.
3. Results
3.1. Patient characteristics
Baseline characteristics are shown in Table 1. All patients were
free of atrial ﬁbrillation at the time of upgrade. Indications of
upgrade included PMS (considered as necessary indication) in
9 patients, and unnecessary indications in 19 patients in whom
upgrade was done during battery exchange or lead replace-
ment (18 patients), and during battery exchange in 1 patient
(who received multisite pacing) with asymptomatic worsening
of LVEF from 51% to 40% after 5 years of VVI pacing.
Table 1 Patient characteristics.
n = 28
Age (years, mean ± SD) 41.4 ± 19
Sex (No.)
Male 17
Female 11
Pacing indication (No.)
SND 1
Idiopathic CHB 20
Postoperative CHBa 7
Time (yrs) in ventricular
pacing (mean ± SD, range)
6.3 ± 2.7 (2–12)
Mode of pacing before upgrade (No.)
VVI 19
VVIR 9
Indications of pacing upgrade (No.)
PMS 9
Unnecessary (opportunistic) indications
During battery exchange 18
During lead replacement 1
SND: sinus node dysfunction, CHB: complete heart block, yrs:
years, PMS: pacemaker syndrome.
a Following repair of ventricular septal defects.
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VVI(R) pacing was upgraded to DDD in 26 patients, VDD in
1 patient, and multisite pacing in 1 patient. Lead impedances,
pacing thresholds and intrinsic electrograms were within
acceptable limits. No procedure related complications were
encountered.
3.3. Follow up
During follow up, there were no reported lead malfunctions.
There was dramatic increase in heart rate (HR) fromTable 2 Patients with intolerance to pacing upgrade (n= 11).
Case No. 1 2 3 4
Symptoms (not requiring hospitalization)
Palpitations +
Dyspnea
Hospitalizations
Angina + +
STEMI +
Dyspnea
Death + +
HR before upgrade (bpm) 60 60 60 60
HR after upgrade (bpm) 85 90 96 77
Relevant ﬁndings
Ischemia on ECG/CEs + + +
Coronary angiography MVD – – –
Nuclear imaging – – – –
Echocardiography
MS
LV systolic dysfunction
(+): Present, (–): not done, (+ve): positive, MVD: multivessel disease, S
infarction, HR: heart rate, bpm: beats per minute, ECG: electrocardiogr67.1 ± 9 to 81.4 ± 10.4 bpm. Intolerance to upgrade occurred
in 11 patients (39.3%), while the remaining 17 patients had
either subjective improvement (8 patients with PMS) or no
clinical events (9 patients). Intolerance to upgrade included
new onset (or worsened) symptoms not requiring hospitaliza-
tion in 3 patients, hospitalization in 7 patients, and death in
3 patients (two died during hospitalization and one had out
of hospital sudden death); all events occurred during the ﬁrst
month after upgrade (mean 2.54 ± 1 weeks).
3.4. Intolerance to upgrade
Among the 11 patients with intolerance to upgrade, only 1 pa-
tient had PMS while 10 patients had unnecessary indications.
The 11 patients had dramatic increase in HR from a baseline
of 60.9 ± 2 to 86.8 ± 7.9 bpm with mean increase of
25.9 ± 8.2 bpm. Three patients developed new onset palpita-
tions/dyspnea that did not require hospitalization and im-
proved after switch back to VVI. Seven patients were
hospitalized; 6 patients had new onset chest pain while 1 patient
was hospitalized for pulmonary congestive symptoms with evi-
dence of moderate mitral stenosis on echocardiogram. Death
occurred in 3 patients; 2 patients died during hospitalization
from acute myocardial ischemia, and 1 patient had out of hos-
pital sudden death following an acute chest pain. Newly diag-
nosed myocardial ischemia following upgrade was evident in
6 patients, with objective signs of ischemia noted on ECG/car-
diac enzymes or coronary angiography in 5 patients, and on nu-
clear imaging in 1 patient (Table 2).
Table 3 shows comparison between patients with intolerance
to upgrade and other patients. Patients with intolerance to up-
grade were older (p< 0.001), with more frequent unnecessary
indications for upgrade (p= 0.049), more rise in HR (p< 0.0
01), and more preexisting undiagnosed myocardial ischemia
that was newly manifested after upgrade (p= 0.001). Univari-
ate logistic regression analysis showed age (p= 0.009) and
HR increase (p= 0.004) to be signiﬁcant predictors for intoler-
ance to upgrade.5 6 7 8 9 10 11
+ +
+
+ + +
+
+
60 65 60 60 65 60 60
92 90 93 96 84 80 72
+ +
– – SVD – – – –
– – – – – – +ve
+
+
VD: single vessel disease, STEMI: ST segment elevation myocardial
am, CEs: cardiac enzymes, MS: mitral stenosis, LV: left ventricle.
Table 3 Comparison between patients with intolerance to upgrade and other patients.
Intolerance to
upgrade (n= 11)
Improvement or no change
after upgrade (n= 17)
p-value
Age (years) 56.8 ± 11.5 31.4 ± 15.8 < 0.001
Sex (M, F) 6,5 11,6 0.70
Time in ventricular pacing (years) 6.8 ± 2.4 6 ± 3 0.45
Mode of ventricular pacing (VVI, VVIR) 11,0 8,9 0.004
Pacing indications (CHB, SND) 11,0 16,1 1.00
PM dependency (No.) 11 14 0.25
Indications of upgrade (No.)
PMS 1 8
Unnecessary 10 9 0.049
HR before upgrade (bpm) 60.9 ± 2 71.1 ± 9.6 < 0.001
HR after upgrade (bpm) 86.8 ± 7.9 77.8 ± 10.4 0.02
Rise in HR (bpm) 25.9 ± 8.2 6 ± 7.5 < 0.001
Preexisting undiagnosed myocardial ischemiaa (No.) 6 0 0.001
M: Male, F: Female, CHB: complete heart block, SND: sinus node dysfunction, PM: pacemaker, PMS: pacemaker syndrome, HR: heart rate,
bpm: beats per minute.
a Rertospectively diagnosed on work up.
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Upgrade of VVI(R) to physiologic pacing is indicated in pa-
tients with PMS, but is also practiced in asymptomatic patients
during battery exchange or lead replacement. The rationale be-
hind this ‘‘opportunistic’’ upgrade may be based on the clinical
trials that demonstrated superiority of dual chamber pacing
over ventricular pacing.7–9 However, these data are applied
in initial pacing mode selection, and not necessarily applied
in pacing upgrade. Moreover, further mode selection trials
showed conﬂicting results,1–4,10,11 indicating that the physio-
logic AV synchrony in dual chamber pacing may be offset
by the cumulative hazards of ventricular pacing. However,
pacing upgrade clearly offers symptomatic beneﬁt in patients
with PMS; a condition that affects 2–83% of patients with
VVI(R) pacing.7,12 On the other hand, it is unknown whether
asymptomatic patients with long standing VVI pacing will
beneﬁt from upgrade or whether the acute hemodynamic
changes of physiologic pacing will produce symptoms.
We reviewed the data of 28 patients subjected to pacing up-
grades after 2–12 years of ventricular pacing. Over 3 month-
follow up, 8 out of 9 patients with PMS were the only patients
who had symptomatic beneﬁts. This is in agreement with Hil-
dick-Smith et al. study that showed greatest symptomatic ben-
eﬁt of upgrade to be in those with PMS, with least clinical
improvement seen in those who underwent upgrade for non-
speciﬁc breathlessness or fatigue.5
In this study, we introduce the concept of ‘‘intolerance to
upgrade’’ that was not reported (or overlooked) in other stud-
ies. Eleven patients in our study (39.3%) had symptoms, hos-
pitalizations, and deaths following upgrade. This unexpected
outcome could be explained by the dramatic rise in HR
(25.9 ± 8.2 bpm) and the increase in preload due to restored
AV synchrony. This acutely unmasked preexisting undiag-
nosed myocardial ischemia in 6 patients, decompensated 1 pa-
tient with underlying MS, and produced symptoms in 3
patients. In addition, 1 patient had acute – out of hospital –
chest pain and sudden death.
Previous studies mainly focused on the beneﬁts of upgrade;
however, the minority of patients with no preference to phys-iologic pacing following upgrade was not subjected to proper
analysis. Ho¨ijer et al. reported that 16 out of 19 patients pre-
ferred DDDR over VVIR mode following pacing upgrade with
signiﬁcant improvement in quality of life, while 2 patients pre-
ferred VVIR over DDDR mode and 1 patient was undecided13
Sulke et al. reported that 12 out of 16 patients preferred DDD
over VVI mode following opportunistic upgrade, while 2 pa-
tients had no preference to either mode.14 Hildick-Smith et
al. reported one case with readmission to hospital with chest
pain following pacing upgrade.5 Of note, all patients with
intolerance to upgrade in our study were PM dependents with
large atrial-ventricular rate mismatch on ECG. Upgrade in this
category of patients could put them at sudden hemodynamic
stress. We found that old age and large increase in HR follow-
ing upgrade were signiﬁcant predictors for intolerance.
Several studies have shown that high HR is an independent
predictor of cardiac and non cardiac mortality in middle-aged
and elderly subjects.15–17 There was sharp rise inmortality when
the clinic-measured HR exceeded 80 bpm.15,18 Rapid HR in-
creases sheer stress, myocardial work load, and oxygen con-
sumption. It is also strongly associated with the clustering of
risk factors, increased sympathetic tone, and the susceptibility
to arrhythmias and sudden cardiac death.19–21 Patients with
intolerance to upgrade in our study had already high atrial rate
during VVI pacing. The conversion of electric rate into mechan-
ical rate could precipitate clinical events in patients having
already high risk proﬁle and asymptomatic coronary heart dis-
ease. The lesson learnt from this is to pre-treat this population
with negative chronotropes if upgrade is necessary, and to as-
sess their global risk by further work up.
Although there was higher proportion of VVI than VVIR
mode in this study, patients with intolerance to upgrade showed
higher post-upgrade HR than other patients (p= 0.02). This
may indicate that lack of rate responsiveness is not solely the risk
of developing such intolerance, but rather the HR increments.
In contrast to other studies, our study showed the worst case
scenario that can occur following upgrade to dual chamber pac-
ing; a pacing mode that has long been called ‘‘physiologic’’. We
claim that asymptomatic patients in chronic VVI pacing are
long adapted to a certain hemodynamic status that can be
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ular ﬁlling occurs. Furthermore, there is evidence from large tri-
als that physiologic pacing is equal to VVI(R) pacing in terms of
mortality, heart failure, stroke, atrial ﬁbrillation and quality of
life.1–3,10,11 Therefore, upgrade indications may be better tai-
lored to individual patients, and if dual chamber pacing is
thought to offer beneﬁt, it is better to be done at the initial
implantation rather than to rely on possible future upgrade.
In this study, there were no procedure related complica-
tions. However, Hildick-Smith et al. reported procedural
complications in 20 out of 44 patients who underwent pacing
upgrade including ventricular arrhythmias, hematoma, infec-
tion, and atrial lead displacement.5 Among 8 patients in their
series who had opportunistic upgrades, 4 had procedural com-
plications. This further questions the necessity of pacing up-
grade in asymptomatic stable patients.
5. Limitations
The study is retrospective that focused on some deleterious ef-
fects of upgrade in certain category of patients over the short
term follow up. However, this does not preclude possible long
term beneﬁts in other patients.
6. Conclusions
Upgrade of ventricular pacing to physiologic pacing offers
clinical beneﬁt in patients with PMS. Upgrade in asymptom-
atic patients can result in short term adverse clinical outcome.
Pacing upgrade is not recommended to be routine practice,
and should be individualized to selected patients.
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